Muhammad Alam, MD
Nephrology · Little Rock, ARNPI 1932202819
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,815 of the $2,111 with a category attached, or 86.0%. It is spread thinly across 19 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $457 and has fallen 64.4% since, to $163 in 2025.
Across 108 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$289
- Mallinckrodt Hospital Products Inc.$255
- AstraZeneca$248
- Fresenius USA Marketing, Inc.$246
- GSK$202
- Otsuka America Pharmaceutical, Inc.$158
- plus $712 from 13 others
What the payments were for
- Food & beverage$1,81586%
- Education$29514%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 14 | $289 |
| Mallinckrodt Hospital Products Inc. | 8 | $255 |
| AstraZeneca(2 entities) | 15 | $248 |
| Fresenius USA Marketing, Inc. | 14 | $246 |
| GSK | 12 | $202 |
| Otsuka America Pharmaceutical, Inc. | 6 | $158 |
| Amgen(2 entities) | 7 | $127 |
| Aurinia Pharma U.S., Inc. | 6 | $120 |
| OPKO Pharmaceuticals, LLC | 6 | $107 |
| Akebia Therapeutics Inc | 4 | $67 |
| Mallinckrodt Enterprises LLC | 4 | $63 |
| Calliditas Therapeutics US Inc. | 3 | $43 |
| Ultragenyx Pharmaceutical Inc. | 2 | $42 |
| Vifor Pharma, Inc. | 2 | $40 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Novartis | 1 | $24 |
| Bayer | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Merck | 1 | $14 |
How this compares
$2,111 in reported general payments places this provider in the 65th percentile of 85 nephrology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 45 | $5,940 |
| Calcium Acetate | 47 | $4,973 |
| Nifedipine ErNifedipine | 55 | $1,165 |
| Doxazosin Mesylate | 52 | $652 |
| Midodrine Hcl | 13 | $490 |
| Labetalol Hcl | 15 | $407 |
| Hydralazine Hcl | 39 | $367 |
| Carvedilol | 42 | $245 |
| Furosemide | 45 | $225 |
| Losartan Potassium | 26 | $178 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $155 |
| Fluconazole | 18 | $149 |
| Pantoprazole Sodium | 21 | $146 |
| Potassium Chloride | 16 | $128 |
| Clonidine Hcl | 18 | $81 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Little Rock
- Luis JuncosLittle Rock$66K
- John HeifnerLittle Rock$45K
- John ArthurLittle Rock$7K
- Moses EjioforLittle Rock$6K
- Alex DavidLittle Rock$6K
- Prajwal ChevireddyLittle Rock$3K
- Kashaf RasheedLittle Rock$2K
- Fakhar IjazLittle Rock$2K
- Nithin KarakalaLittle Rock$739
- Garry GlascoLittle Rock$459
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.